INDICATIONS AND USAGE Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules USP and other antibacterial drugs, clindamycin hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
micro labs limited
CLINDAMYCIN HYDROCHLORIDE capsules USP is available in the following strengths, colors and sizes: 75 mg- green transparent (body)/ green transparent (cap), size 3 hard gelatin capsule printed with âMâ on cap and â40â on body filled with white to off white granular powder. Bottles of 100 NDC 42571-250-01 Carton of 90(9Ã10's) Unit-dose Capsules NDC 42571-250-67 150 mg- green transparent (body)/ light blue opaque (cap), size 2 hard gelatin capsule printed with âMâ on cap and â41â on body filled with white to off white granular powder. Bottles of 100 NDC 42571-251-01 Bottles of 500 NDC 42571-251-05 Bottles of 1000 NDC 42571-251-10 Carton of 80(8Ã10's) Unit-dose Capsules NDC 42571-251-23 300 mg- Light blue opaque (body)/ light blue opaque (cap), size 0 hard gelatin capsule printed with âMâ on cap and â42â on body filled with white to off white granular powder. Bottles of 100 NDC 42571-252-01 Bottles of 500 NDC 42571-252-05 Bottles of 1000 NDC 42571-252-10 Store at controlled room temperature 20Â° to 25Â° C (68Â° to 77Â° F) [see USP]. Rx only
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site